Medicamen Biotech Ltd

Medicamen Biotech Ltd

₹ 384 0.34%
28 Mar - close price
About

Medicamen Biotech Ltd develops and markets a wide range of branded and generic formulations in the pharmaceutical industry.[1]

Key Points

Product Offerings
The Company manufactures formulations for anti-retroviral, oncology, cardiovascular, diabetic and hypertension, nutraceutical, and other products. Its key products are Efavirenz, Tenofovir (TDF), Gemcitabine, and Finished Dosage Forms (FDF) of these Products and Bio-Technology. [1]

  • Market Cap 486 Cr.
  • Current Price 384
  • High / Low 904 / 355
  • Stock P/E 43.3
  • Book Value 158
  • Dividend Yield 0.26 %
  • ROCE 10.4 %
  • ROE 8.67 %
  • Face Value 10.0

Pros

  • Company is expected to give good quarter

Cons

  • Company has a low return on equity of 9.56% over last 3 years.
  • Dividend payout has been low at 8.93% of profits over last 3 years
  • Company has high debtors of 169 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
32.92 21.24 27.53 32.52 32.64 22.75 33.09 33.53 35.58 38.67 41.94 43.54 46.50
27.66 16.90 21.49 26.30 26.34 17.79 27.43 27.67 29.71 32.18 34.99 38.89 41.60
Operating Profit 5.26 4.34 6.04 6.22 6.30 4.96 5.66 5.86 5.87 6.49 6.95 4.65 4.90
OPM % 15.98% 20.43% 21.94% 19.13% 19.30% 21.80% 17.10% 17.48% 16.50% 16.78% 16.57% 10.68% 10.54%
0.00 0.54 0.08 0.48 0.83 0.34 0.96 0.52 0.63 0.35 0.38 0.55 0.83
Interest 0.09 0.36 0.04 0.30 0.49 0.56 0.77 0.62 0.68 0.86 0.96 0.91 0.65
Depreciation 0.71 0.41 1.33 1.35 1.57 1.52 1.53 1.62 1.60 1.62 1.69 1.82 1.80
Profit before tax 4.46 4.11 4.75 5.05 5.07 3.22 4.32 4.14 4.22 4.36 4.68 2.47 3.28
Tax % 32.29% 10.95% 12.42% 16.44% 25.64% 14.60% 17.13% 13.04% 10.66% 13.53% 15.81% 39.68% 38.11%
3.01 3.65 4.15 4.22 3.78 2.75 3.59 3.60 3.77 3.77 3.95 1.47 2.03
EPS in Rs 2.46 2.99 3.40 3.45 3.09 2.25 2.94 2.85 2.97 3.07 3.30 1.19 1.60
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
123 125 113 115 141 171
105 106 93 91 117 148
Operating Profit 17 20 20 24 24 23
OPM % 14% 16% 17% 21% 17% 13%
4 2 1 2 2 2
Interest 1 1 2 2 3 3
Depreciation 2 2 3 6 6 7
Profit before tax 18 18 16 18 17 15
Tax % 31% 26% 26% 18% 14%
12 13 12 15 15 11
EPS in Rs 10.28 10.88 9.93 12.20 11.73 9.16
Dividend Payout % 10% 5% 10% 8% 9%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 4%
TTM: 37%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 3%
TTM: -18%
Stock Price CAGR
10 Years: 42%
5 Years: -5%
3 Years: -10%
1 Year: -41%
Return on Equity
10 Years: %
5 Years: %
3 Years: 10%
Last Year: 9%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 12 12 12 12 13 13
Reserves 75 109 121 134 181 187
12 11 19 26 26 29
38 49 42 53 59 68
Total Liabilities 137 181 194 226 279 297
24 34 90 92 93 93
CWIP 15 40 0 0 0 0
Investments 0 0 0 0 0 0
97 107 104 133 186 204
Total Assets 137 181 194 226 279 297

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
4 13 13 4 -6
-15 -37 -18 -8 -6
-4 19 6 4 29
Net Cash Flow -14 -5 1 -0 17

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 129 145 170 200 169
Inventory Days 67 78 27 188 228
Days Payable 134 173 169 302 241
Cash Conversion Cycle 62 51 28 86 156
Working Capital Days 151 152 161 208 216
ROCE % 16% 13% 12% 10%

Shareholding Pattern

Numbers in percentages

9 Recently
Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
44.83% 44.83% 44.83% 43.60% 43.60% 43.60% 43.21% 43.21% 43.21% 43.21% 43.21% 43.21%
0.44% 0.41% 0.35% 0.35% 0.40% 0.35% 1.83% 0.17% 0.19% 0.16% 0.22% 0.22%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.13% 0.20% 0.20% 0.20% 0.20% 0.67%
54.73% 54.75% 54.82% 56.06% 56.01% 56.06% 54.84% 56.42% 56.40% 56.44% 56.38% 55.90%
No. of Shareholders 4,9655,2635,5959,1409,3009,1078,3328,2738,2338,2729,41910,252

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls